In this regard, we chose the APPKM670/671NL.PS1/L166P mouse model25 (subsequently referred to as the APP.PS1 mouse model in this paper), that start to develop amyloid pathology in the cortex at 6 weeks and in the hippocampus at 3–4 months of age, in order to investigate the synergistic effects of tau and amyloid pathology associated with the tau seeding method published by Guo and colleagues17. The gene discussed is MAPT; the disease is amyloidosis.